¼¼°èÀÇ ÀÓ»ó½ÃÇè¿ë »ý¼ºÇü AI ½ÃÀå(2025-2029³â)
Global Generative AI in Clinical Trial Market 2025-2029
»óǰÄÚµå : 1783905
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 225 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,513,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,622,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÓ»ó½ÃÇè¿ë »ý¼ºÇü AI ½ÃÀåÀº 2024-2029³â µ¿¾È 5¾ï 7,270¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ µ¿¾È CAGR 30.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè¿ë »ý¼ºÇü AI ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ Æ÷ÇÔÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÓ»ó °³¹ß ºñ¿ë ¹× ÀÏÁ¤ ´ÜÃà, ÀÓ»ó½ÃÇèÀÇ º¹À⼺ ¹× ¸ÖƼ¸ð´Þ µ¥ÀÌÅÍÀÇ ±ÞÁõ¿¡ ´ëÇÑ °ü¸®, ±Þ¼ÓÇÑ ±â¼ú ¼º¼÷°ú Àü·«Àû ÀÌÁ¾ »ê¾÷°£ Çù¾÷ µî Á¾ÇÕÀûÀÎ ¿ä±¸°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2025³â
Á¾·á ¿¬µµ 2029³â
¿¹Ãø ±â°£ 2025-2029³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³âºñ 28.2%
CAGR 30.8%
Áõ°¡¾× 5¾ï 7,270¸¸ ´Þ·¯

º» Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü¿©ÀÚµéÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ Á¤º¸¿Í 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î Á¶ÇÕÇÏ¿© ½Ç½ÃµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼­¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³â µ¿¾È ÀÓ»ó½ÃÇè¿ë »ý¼ºÇü AI ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î µµ¸ÞÀκ° ¹× ¸ÖƼ¸ð´Þ »ý¼º ¸ðµ¨ÀÇ ºÎ»óÀ» ²Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI-as-a-service »ýŰè¿Í ½ÉÃþÀûÀÎ Ç÷§Æû ÅëÇÕÀÇ È®»ê, ±×¸®°í ¼ø¼ö ÀÚµ¿È­¿¡¼­ Àΰ£ È®Àå ¹× ½Å±Ô ¹ß°ßÀ¸·ÎÀÇ ÁøÈ­Àû ÀüȯÀº ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå »óȲ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå Five Forces ºÐ¼®

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : Àü°³º°

Á¦7Àå ½ÃÀå ¼¼ºÐÈ­ : ¿ëµµº°

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå °í°´ »óȲ

Á¦10Àå Áö¿ªº° »óȲ

Á¦11Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå °æÀï ºÐ¼®

Á¦14Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The generative AI in clinical trial market is forecasted to grow by USD 572.7 mn during 2024-2029, accelerating at a CAGR of 30.8% during the forecast period. The report on the generative AI in clinical trial market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by overarching imperative to reduce clinical development costs and timelines, management of increasing trial complexity and proliferation of multimodal data, and rapid technological maturation and strategic cross-industry collaborations.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 202528.2%
CAGR30.8%
Incremental Value$572.7 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's generative AI in clinical trial market is segmented as below:

By Deployment

By Application

By End-user

By Geographical Landscape

This study identifies the ascendance of domain-specific and multimodal generative models as one of the prime reasons driving the generative AI in clinical trial market growth during the next few years. Also, proliferation of ai-as-a-service ecosystem and deep platform integration and evolutionary shift from pure automation to human augmentation and novel discovery will lead to sizable demand in the market.

The report on the generative AI in clinical trial market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading generative AI in clinical trial market vendors that include A.I. VALI Inc., Acclinate Inc., AiCure, Antidote Technologies Inc., Claritrics Inc., ConcertAI Inc., Deep 6 AI Inc., Exscientia plc, Innoplexus, Intelligencia Inc., Median Technologies SA, Medidata, Opyl Ltd, Owkin Inc., SiteRx Inc., Tempus Labs Inc., Trials.ai, and Unlearn.ai Inc. Also, the generative AI in clinical trial market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Five Forces Analysis

6 Market Segmentation by Deployment

7 Market Segmentation by Application

8 Market Segmentation by End-user

9 Customer Landscape

10 Geographic Landscape

11 Drivers, Challenges, and Opportunity/Restraints

12 Competitive Landscape

13 Competitive Analysis

14 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â